Chronic oral administration of ginseng extract results in behavioral change but has no effects in mice models of affective and anxiety disorders

被引:17
作者
Einat, Haim [1 ]
机构
[1] Univ Minnesota, Coll Pharm, Duluth, MN 55812 USA
关键词
natural products; animal models; depression; anxiety; bipolar disorder; neuroprotection;
D O I
10.1002/ptr.2024
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Ginseng is a popular 'tonic' herb in Chinese traditional medicine with diverse biological activity. The core of ginseng's therapeutic abilities is thought to be its neuroprotective actions in increasing cellular resilience. These actions coincide with novel theories of affective and anxiety disorders and raise the possibility that ginseng may serve as medication for these common and devastating diseases. The present study was designed to explore the possible effects of chronic ginseng extract, administered in a clinically relevant schedule (similar to antidepressants) in animal models of affective and anxiety disorders. Groups of mice received chronic oral treatment with ginseng extract (500 mg/kg/day for 3 weeks) and were tested in a large open field, in the emergence test for anxiolytic activity, the forced swim test for antidepressant activity and the amphetamine hyperactivity test for mood stabilizing activity. Chronic ginseng had a significant effect on reducing spontaneous locomotor activity in the open field test but not on the distribution of activity and had no influence on the performance of mice in any of the specific models. Although the extract used in this study contained significant levels of ginsenosides, detailed analysis of the brain levels of the active ingredients of ginseng may be needed to make a far reaching conclusion. However, the doses and schedule of administration of ginseng used in the present study induced some behavioral changes but did not influence affective- and anxiety-like measures. Copyright (c) 2006 John Wiley & Sons, Ltd.
引用
收藏
页码:62 / 66
页数:5
相关论文
共 37 条
[1]   Intra- and interstrain differences in models of "behavioral despair" [J].
Bai, F ;
Li, X ;
Clay, M ;
Lindstrom, T ;
Skolnick, P .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2001, 70 (2-3) :187-192
[2]  
BENJAMIN J, 1995, PSYCHOPHARMACOL BULL, V31, P167
[3]   Behavioral profile of rats submitted to session 1-session 2 in the elevated plus-maze during diurnal/nocturnal phases and under different illumination conditions [J].
Bertoglio, LJ ;
Carobrez, AP .
BEHAVIOURAL BRAIN RESEARCH, 2002, 132 (02) :135-143
[4]   Mood stabilizers: protecting the mood... protecting the brain [J].
Brunello, N .
JOURNAL OF AFFECTIVE DISORDERS, 2004, 79 :S15-S20
[5]  
Brunton L., 2005, Goodman and Gilman's The Pharmacological Basis of Therapeutics, VEleventh
[6]   Identification of anxiolytic ingredients in ginseng root using the elevated plus-maze test in mice [J].
Carr, MN ;
Bekku, N ;
Yoshimura, H .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 531 (1-3) :160-165
[7]   Anxiolytic-like effects of ginsenosides on the elevated plus-maze model in mice [J].
Cha, HY ;
Park, JH ;
Hong, JT ;
Yoo, HS ;
Song, S ;
Hwang, BY ;
Eun, JS ;
Oh, KW .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2005, 28 (09) :1621-1625
[8]   Finding the intracellular signaling pathways affected by mood disorder treatments [J].
Coyle, JT ;
Duman, RS .
NEURON, 2003, 38 (02) :157-160
[9]   Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests [J].
Crawley, JN .
BRAIN RESEARCH, 1999, 835 (01) :18-26
[10]  
Duman RS, 2002, EUR PSYCHIAT, V17, p306S